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Abstract
There are over 120 types of brain tumor and approximately 45% of primary brain tumors
are gliomas, of which glioblastoma multiforme (GBM) is the most common and aggressive
with a median survival rate of 14 months. Despite progress in our knowledge, current
therapies are unable to effectively combat primary brain tumors and patient survival
remains poor. Tumor metabolism is important to consider in therapeutic approaches and is
the focus of numerous research investigations. Lactate dehydrogenase A (LDHA) is a
cytosolic enzyme, predominantly involved in anaerobic and aerobic glycolysis (the
Warburg effect); however, it has multiple additional functions in non-neoplastic and neo-
plastic tissues, which are not commonly known or discussed. This review summarizes what
is currently known about the function of LDHA and identifies areas that would benefit from
further exploration. The current knowledge of the role of LDHA in the brain and its
potential as a therapeutic target for brain tumors will also be highlighted. The Warburg
effect appears to be universal in tumors, including primary brain tumors, and LDHA
(because of its involvement with this process) has been identified as a potential therapeutic
target. Currently, there are, however, no suitable LDHA inhibitors available for tumor
therapies in the clinic.
LACTATE DEHYDROGENASE
Lactate dehydrogenase (LDH) is a tetrameric enzyme, belonging
to the 2-hydroxy acid oxidoreductase family, which increases the
rate of the simultaneous inter-conversion of pyruvate to lactate and
nicotinamide adenine dinucleotide (NAD)H to NAD+ by 14 orders
of magnitude (10) (Figure 1). The reaction involves the transfer of
a hydride ion from NADH to the C2 carbon of pyruvate (99) and
is commonly used by cells for anaerobic respiration. There are four
LDH genes: LDHA, LDHB, LDHC and LDHD (Figure 2). LDHA,
LDHB and LDHC are L isomers, whereas LDHD is a D isomer.
The L isomers use or produce L-lactate, which is the major
enantiomer found in vertebrates.
The human LDHA gene is located on chromosome 11p15.4, the
transcribed protein has 332 amino acids, a predicted molecular
weight of 37 kDa and 24 splice variants; the human genome also
contains several non-transcribed LDHA pseudogenes (32, 126).
Evolutionarily, LDHA and LDHB are thought to have arisen from
the duplication of a single LDHA-like LDH gene (82). LDHC, a
testes-specific gene, is also thought to have evolved in mammals
from the duplication of the LDHA gene after the A-B duplication
(82).
LDHA is also known as the M subunit as it is predominantly
found in skeletal muscle, and LDHB is also known as the H
subunit as it is predominantly found in the heart. Unlike the other
LDH genes, which can form only homotetramers, LDHA and
LDHB can form homo- or heterotetramers. There are five
isoenzymes of LDH that can be made from the M and H subunits:
LDH-1 (4H), LDH-2 (3H, 1M), LDH-3 (2H, 2M), LDH-4 (1H,
3M), and LDH-5 (5M) (Figure 2). LDH-1 and LDH-5 have iden-
tical active site regions and only differ in 81 out of 332 amino acid
positions, most of which are found in the first 22 and last 38
residues and have a minimal effect on the overall structure (104).
The N-terminus of LDHA is important for structural stability as
deletion of up to 10 amino acids from the N-terminus increases
instability, flexibility, inactivity and sensitivity to denaturing envi-
ronments (150). Although structurally they are very similar, each
LDH isoenzyme has different kinetic properties and studies
suggest that their distinct kinetics are a result of the differences in
charged surface residues bordering the active site (104). Each
LDHA subunit has a net charge of −6 and a higher affinity for
pyruvate, preferentially converting pyruvate to lactate and NADH
Figure 1. The reaction catalyzed by lactate dehydrogenase (LDH). LDH
catalyzes the reversible conversion of pyruvate and NADH to lactate and
NAD+.
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to NAD+, whereas each LDHB subunit has a net charge of +1 and
a higher affinity for lactate, preferentially converting lactate to
pyruvate and NAD+ to NADH (61, 104).
LDHA has many roles in non-neoplastic and neoplastic cells
which are described in detail in the following text and summarized
in Figure 3. The genes highlighted in the text, which have been
reported to be associated with the function of LDHA, have also
been compiled in Table 1. Most of the research into the function of
LDHA has been demonstrated in non-central nervous system
(CNS) tumors, some of which commonly metastasize to the brain;
however, links to primary CNS tumors will also be a focus in this
review.
THE ROLE OF LDHA IN CELLULAR
METABOLISM
Under normal physiological conditions, pyruvate is generated
from glucose by glycolysis and enters the citric acid cycle in the
mitochondria where it is oxidatively decarboxylated to form
acetyl-CoA, which is used to fuel oxidative phosphorylation, theo-
retically generating 36 net adenosine triphosphate (ATP) per mol-
ecule of glucose. However, when oxygen becomes scarce, cells are
unable to use oxidative phosphorylation to efficiently generate
ATP. In this scenario, glycolysis becomes the main generator of
ATP, producing 2 net ATP per molecule of glucose. However,
NAD+ is required to enable the sixth step of glycolysis as
glyceraldehyde phosphate dehydrogenase (GAPDH) uses NAD+
to convert glyceraldehyde 3-phosphate (GADP) to D-1,3-
bisphosphoglycerate (1,3BPG). NAD+ is usually regenerated
through oxidative phosphorylation by the electron transport chain,
so when the oxygen supply is restricted, NAD+ is regenerated from
NADH by LDHA in order to maintain glycolysis, generating
lactate as a by-product; this is known as anaerobic glycolysis
(Figure 4). Although it is less efficient, anaerobic glycolysis is 100
times faster than oxidative phosphorylation, enabling it to fulfill
the short-term energy requirements in the absence of sufficient
oxygen at the expense of a greater consumption of glucose.
Different tissues in the body have different metabolic rates,
energy requirements and functions, which are often reflected in
their LDHA : LDHB ratio. For example, approximately 40% of
lactate in the circulation is released by skeletal muscle, whereas
the liver and kidneys predominantly absorb lactate from the circu-
lation and oxidize it to synthesize glucose (1). Brain metabolism is
clearly complex as it responds dynamically to changes in blood
Figure 2. Lactate dehydrogenase (LDH) homo- and tetramer formation. The LDH isoenzymes LDH-1, LDH-2, LDH-3, LDH-4 and LDH-5 are made up
of different ratios of LDH-M and LDH-H subunits, transcribed from LDHA and LDHB, respectively. The LDHC tetramer is only made up of LDHC
subunits.
Figure 3. Schematic showing processes that
are reportedly affected by lactate
dehydrogenase A (LDHA). LDHA transcription
is regulated by the genes and proteins listed
in Table 2. LDHA has been reported to be
involved with the processes listed in the
orange box. LDHA has also been reported to
indirectly influence the processes listed in the
red box via aerobic glycolysis and lactate
production.
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glucose and lactate concentrations. A study of six normal physi-
cally active men found that at rest, the brain oxidizes approxi-
mately 10% of blood L-lactate, fueling 8% of cerebral energy
requirements, but still releases a small amount of net L-lactate
(129). However, in response to physical exertion and
hyperlactatemia, the brain takes up net L-lactate (94, 129), which
contributes up to 60% of brain metabolism with cerebral lactate
oxidation thought to use 33% of lactate (1, 94).
Cancer cell metabolism is modified when compared with that of
normal cells and is known as the Warburg effect or aerobic
glycolysis, first observed by Otto Warburg in the 1920s (138).
Cancer cells use LDHA to elevate the rate of glycolysis, ATP and
lactate production even when oxygen is available (55). Studies
suggest that the switch to an aerobic glycolysis metabolic pheno-
type benefits cancer cells by avoiding generation of oxidative
stress by the electron transport chain (68). Furthermore, by using
aerobic glycolysis to generate ATP, cancer cells can use the inter-
mediates of the citric acid cycle (which are regenerated by glucose
and pyruvate) for anabolic reactions to synthesize the lipids, fatty
acids and nucleotides required for rapid cell proliferation (22,
131). As discussed in previous reviews, this abnormal metabolism
used by cancer cells is an attractive target for cancer-specific
therapies (97, 147).
REGULATION OF LDHA SYNTHESIS
The LDHA promoter region has long been known to contain the
consensus sequences for, and be regulated by, major transcription
factors: hypoxia-inducible factor 1 (HIF1) and c-Myc (29, 74, 111,
116). More recently, forkhead box protein M1 (FOXM1) (20) and
Kruppel-like factor 4 (KLF4) (114) were identified as transcrip-
tional regulators of LDHA; however, LDHA regulation is complex
and is far from being completely understood. LDHA transcription
is also known to be influenced by many factors including lactate
(77), cyclic adenosine monophosphate (cAMP) (85), estrogen
(11), ErbB2 and heat shock factor 1 (148) and is likely to be
influenced by other unknown factors (Table 2).
HIF1α is the alpha subunit of transcription factor HIF1 that is
usually degraded under normoxic conditions by prolyl
hydroxylase. However, under hypoxic conditions, HIF1α is stabi-
lized and forms the HIF1 transcription factor with the constitu-
tively expressed subunit HIF1β. HIF1 promotes the transcription
of target genes involved in metabolism (including LDHA),
angiogenesis and apoptosis, which support cell survival in hypoxic
environments. However, HIF1α is also often stabilized in cancers,
including brain tumors (105), by other factors such as
overexpression of pyruvate kinase isozymes M2 (PKM2), Ras,
Table 1. List of genes and proteins reported to be associated with lactate dehydrogenase A (LDHA) activity.
Gene/Protein Association with LDHA function Reference
AUF Gene transcription (100)
DNA polymerase-α complex Gene transcription (42)
OCA-S Gene transcription (21, 43, 149)
ATP-sensitive K+ channel Channel complex regulation (19)
SUR2A Channel complex regulation (19)
Kir6.2 Channel complex regulation (19)
NDPK-A Channel complex regulation (51)
AMPK Channel complex regulation (51)
CK2 Channel complex regulation (51)
IMT-1 Molecular chaperone (34)
Bax Apoptosis (137, 144)
PARP Apoptosis (108, 137)
Caspase 9 Apoptosis (113, 137)
Caspase 3 Apoptosis (113)
Bcl-2 Apoptosis (108, 137)
P53 Apoptosis (2)
Bcl-XL Apoptosis (108, 153),
XIAP Apoptosis (108)
Mcl-1 Apoptosis (153)
Rcl Tumor growth/survival (75)
IDH Tumor growth/survival (14)
Oct-4 Tumor growth/survival/cancer stem cell (145)
MMP-2 Tumor migration/metastasis (6, 113)
E-cadherin Tumor migration/metastasis (113)
FAK Tumor migration/metastasis (113)
THBS-1 Tumor migration/metastasis (110)
TGF-β2 Tumor migration/metastasis (6, 110)
Tropomyosin isoform (Tm5) Tumor migration/metastasis (3)
VEGF Tumor angiogenesis (36, 54, 65, 113)
VEGFR2 Tumor angiogenesis (36)
NKG2D ligands: ULBP-1 and MICB Tumor evasion of immune response (17)
Lactate Transcription regulation of LDHA, tumor angiogenesis, tumor
migration/metastasis, tumor evasion of immune response
(6, 37, 69, 77, 101, 110, 125)
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proto-oncogene tyrosine-protein kinase Src and ErbB2 and consti-
tutive activation of the phosphatidylinositol-4,5-bisphosphate
3-kinase (PI3k), protein kinase B (Akt) or mammalian target
of rapamycin (mTOR) pathway (79, 83). Furthermore,
overexpression of HIF1α is associated with LDHA overexpression
and a significantly poorer survival in some cancers (62, 78). Pro-
motion of LDHA transcription by HIF1 has also been shown to be
enhanced when cAMP binds to the cAMP response element (CRE)
in the LDHA promoter region (29). However, LDHA regulation by
HIF1 is clearly complex as studies have shown that LDHA creates
a positive feedback loop, upregulating HIF1α expression under
normoxic conditions by enhancing lactate production, which
inhibits prolyl hydroxylase (77). On the other hand, studies in
HT29 cells have shown that HIF1α expression was upregulated
more in LDHA knockdown clones than control clones under
hypoxic conditions, but unusually they also found that the
upregulation of HIF1α in the LDHA-silenced clones did not cor-
relate with the expression of other HIF1-regulated genes: carbonic
anhydrase IX (CAIX) and vascular endothelial growth factor
(VEGF) (70).
The c-Myc proto-oncogene is known as a “master regulator” as
it regulates many key cell processes including cell cycle, growth,
proliferation and apoptosis and is usually tightly controlled. For
example, during exercise, c-Myc expression and therefore LDHA
expression are down-regulated by peroxisome proliferator-
activated receptor-γ co-activator 1α (PGC-1α) in oxidative muscle
fibers to promote lactate uptake and lactate oxidation to maintain
lactate homeostasis (122). However, c-Myc expression is often
deregulated in brain tumor cells, including the most metastatic
subgroup of medulloblastoma (MB) (group 3) (124) and has been
shown to transform rat fibroblasts by up-regulating LDHA (74,
116). LDHA has also been shown to cooperate with Rcl, another
c-Myc target gene of unknown function, to induce anchorage-
independent cell growth in vitro and to induce tumor formation in
vivo (75). The overexpression of c-Myc can also enhance LDHA
expression by promoting HIF1α stabilization under normoxic
conditions and enhancing HIF1α expression under hypoxic con-
ditions. Again, the regulation of LDHA by c-Myc is not straight-
forward; studies in gastric cancer suggest that LDHA may be
involved in a negative feedback loop, as inhibition of LDHA
increases c-Myc expression (145). Although HIF1 and c-Myc have
long been known to be LDHA transcription factors, there are still
many aspects that are unclear and the precise mechanism in which
they work and how their transcription of LDHA is regulated should
continue to be actively investigated.
Recent studies have found that LDHA is also transcriptionally
regulated by FOXM1 (20). FOXM1 is an oncogenic transcription
factor elevated in many types of cancer and is known to regulate
the cell cycle, invasion, metastasis and angiogenesis (33, 60). Kim
et al conducted studies that demonstrated that FOXM1 binds to the
LDHA promoter region, upregulates LDHA mRNA transcription,
LDHA protein expression, glucose consumption and lactate pro-
duction (20). Furthermore, inhibition of LDHA activity dimin-
ished the enhanced glucose consumption and lactate production
effects of FOXM1 overexpression, while in vivo studies estab-
lished that upregulation of FOXM1 promoted LDHA expression,
cancer growth and metastasis (20). Another recent study on
tissue and cell lines found that LDHA expression was significantly
positively correlated with pancreatic tumor progression and
de-differentiation, whereas KLF4, a transcription factor normally
expressed in terminally differentiated epithelial cells, was
significantly negatively correlated (114). Further examination
found that KLF4 suppression significantly increased LDHA
expression, whereas KLF4 overexpression significantly inhibited
aerobic glycolysis, tumor growth and LDHA expression both in
vitro and in vivo (114). Shi et al went on to find two KLF4 binding
sites between −371 and −367 base pairs (bp), and −1310 and 1306
bp of the LDHA promoter region (114). These recent studies show
promise and it would be interesting to see if the results are cor-
roborated in different tissues, including brain tumors, as FOXM1
Figure 4. Anaerobic glycolysis. Lactate dehydrogenase A (LDHA) is
required to maintain glycolysis and ATP production in the absence of
sufficient oxygen by regenerating NAD+ form NADH. Lactate is gener-
ated as the end by-product of this reaction. The reaction consumes 2
ATP but creates 4 ATP, generating 2 net ATP per molecule of glucose.
Table 2. List of genes and proteins reported to regulate lactate
dehydrogenase A (LDHA).
Gene/Protein Mechanism of LDHA regulation Reference
HIF1 Transcription regulation of LDHA (29, 111)
C-Myc Transcription regulation of LDHA (74, 116)
FOXM1 Transcription regulation of LDHA (20)
KLF4 Transcription regulation of LDHA (114)
cAMP Transcription regulation of LDHA (85)
Estrogen Transcription regulation of LDHA (11)
ErbB2 Transcription regulation of LDHA (148)
Heat shock
factor 1
Transcription regulation of LDHA (148)
FGFR1 Post-transcriptional regulation of LDHA (26)
SIRT2 Post-transcriptional regulation of LDHA (146)
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is a marker of poor prognosis in MB (102) and regulates glioma
tumorigenicity (76). KLF4 is also suppressed in MB (89) and
mutated in meningioma (106).
POST-TRANSCRIPTIONAL REGULATION
OF LDHA
Like many enzymes, LDHA post-transcriptional activity is regu-
lated by phosphorylation and acetylation of amino acid residues.
The oncogenic receptor tyrosine kinase FGFR1, expressed in men-
ingioma and glioma (128), has been shown to directly phosphor-
ylate LDHA atY10 andY83 (26).Y10 phosphorylation of LDHA,
which is common in many human cancers, promotes active,
tetrameric LDHA formation, whereas phosphorylation ofY83 pro-
motes NADH substrate binding (26). Recently, Zhao et al have
also shown that deacetylation of LDHA at lysine-5 is regulated by
SIRT2 deacetylase in pancreatic cancer (146). Furthermore, they
found that the acetylation of LDHA at K5 leads to degradation of
LDHA and proposed that it was caused by chaperone-mediated
autophagy (CMA) through interaction with HSC70 chaperone and
lysosomes (146). Continued research on the mechanism of LDHA
deactivation and degradation could aid in the development of novel
therapeutic agents.
THE ROLE OF LDHA IN THE
CELL CYCLE
It has been known since the 1960s that LDHexpression fluctuates as
cells progress through the cell cycle (56, 57). In 1991 Pan et al
found that LDHA expression in normal human T and B lympho-
cytes increases when the cells are activated and proliferating, dem-
onstrating that LDH isoenzymes can be used as proliferative
markers (95). They also observed that LDHA expression intensity
was at its greatest level whenmajority ofT and B lymphocytes were
in S/G2/M phase and that LDHA expression decreased as the cells
returned to their resting state (95). LDH has since been used as a
marker of cell proliferation and mobilization of CD34+ cells for
stem cell apheresis (24, 25). More recent studies have begun to
clarify the role of LDHA in the cell cycle. For example, inhibition of
LDHA activity induced G2/M cell cycle arrest by downregulating
the CDK1/cyclin B1 pathway in cell lines (144), while S-phase
transition was significantly induced by overexpression of LDHA
(108). The mechanism by which LDHA affects the cell cycle
warrants additional exploration.
LDHA AS A TRANSCRIPTION FACTOR
In the 1980s, it was reported that although LDHA is predominantly
found in the cytoplasm, it is also localized in the nucleus of many
tumors and binds to ssDNA and mRNA (41, 62, 63, 100, 112).
Pioli et al showed that LDHA specifically binds to the AU-rich
element of GM-CSF (granulocyte-macrophage colony-stimulating
factor) RNA and interacts directly with AUF1 (a regulator of
mRNA) (100). Furthermore, LDHA has been shown to upregulate
DNA synthesis catalyzed by the DNA polymerase-α complex up
to fivefold (42) and bind translationally active RNA in polysomes
(100). LDHA with tyrosine phosphorylation has also been
reported as localized to the nucleus, suggesting that tyrosine
phosphorylation may play an essential role in LDHA function in
the nucleus (151). Together, these studies suggest that LDHA has
a role in transcription, but the mechanism is still unclear and few
specific targets have been identified. Although most of these
studies were conducted over two decades ago, their importance
must not be forgotten and should be investigated in more depth
using modern technologies.
L-LDH is critical in the organization of the Oct-1 coactivator S
(OCA-S) transcription complex which regulates S-phase histone
2B (H2B) transcription in a NADH/NAD+-dependent manner (21,
43, 149). The OCA-S complex was sensitive to cellular redox
levels as H2B transcription decreased when NAD+ was depleted
(21). Redox status and therefore metabolic status could be linked
to gene switching, a mechanism that is commonly seen in
prokaryotes and requires further exploration in relation to human
DNA transcription. Collectively, these studies suggest one way in
which LDHA could regulate transcription is through regulating the
cellular redox state. However, these studies have not specifically
identified whether LDHA or LDHB is involved predominantly or
whether they have different enzymatic influences on the OCA-S
transcription complex.
OTHER ROLES OF LDHA
LDHA has been shown to be an integral part of the sarcolemmal
ATP-sensitive K+ (KATP) channel in the heart, associating with
the KATP channel subunits, SUR2A and Kir6.2, at the C-terminus
and N-terminus, respectively. KATP channels are closed in
response to high intracellular ATP but open during ischemia to
prevent apoptosis. The generation of lactate by LDHA during
ischemia allows the channel to open in the presence of ATP, pro-
tecting the cell from death caused by calcium accumulation (19).
In this way, LDHA is able to couple KATP channel activity with
the metabolic status of the cell and protect against cell death by
ischemia. Interestingly, KATP channel expression is elevated in
glioma and studies have shown that inhibition of KATP channels
resulted in decreased glioma cell proliferation (47). The same
group went on to discover that LDHA is part of the nucleoside
diphosphate kinase-A (NDPK-A) isoform of the liver cytosolic
substrate channeling complex (51). Furthermore, they found that
LDH also has a role in regulating the activity of the liver cytosolic
substrate channeling complex in response to the metabolic status
of the cell. Knockdown of LDHA and LDHB revealed that LDHA
upregulates the activity of AMPK and CK2, other components of
the substrate-channeling complex, whereas LDHB inhibits their
activity (51). Together, these studies show how LDHA plays a
critical role in the regulation of channel complexes in the heart and
liver in response to the metabolic status of the cell. It is possible
that LDHA could play similar roles in many other channel com-
plexes. Other roles of LDHA also include acting as a molecular
chaperone or as an association molecule during the differentiation
of thymocytes (34).
LDHA IN THE BRAIN AND CEREBRAL
SPINAL FLUID
The brain is a very complex organ with high energy needs that
change over a lifespan. Studies have shown that the human brain
uses high levels of aerobic glycolysis during fetal growth and
development, which increases during childhood, but then switches
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to oxidative phosphorylation which is seen predominantly in the
adult brain (39). The ratios of LDHA to LDHB, which determine
either aerobic glycolysis or oxidative phosphorylation, were exam-
ined in human fetuses at different stages of gestation. They found
that LDHB expression decreased from 18% at 16 weeks to 15% at
40 weeks, compared to 23% in adult brains. LDHA increased from
8% at 16 weeks to 16% at 40 weeks, compared to 6% in adult
brains (121). More recent studies have examined the distribution
of LDHA and LDHB within various regions of the brain. Studies
in mouse and rat brains showed that LDHB mRNA expression was
predominant throughout the brain with the exception of strong
LDHA expression in the hippocampal regions CA1, CA2 and
CA4, the ventromedian hypothalamic nucleus, and the dorsal
raphe nucleus as well as moderate expression in the cerebral cortex
(71, 109). Moreover, a study of 33 neurologically normal young
adults using magnetic resonance imaging (MRI) and positron
emission tomography (PET) scans found that aerobic glycolysis
was significantly elevated in a few regions, particularly the medial
and lateral parietal and prefrontal cortices, whereas the cerebellum
and medial temporal lobes had significantly lower levels of aerobic
glycolysis than the rest of the brain (130). Recent studies have
shown that the regions of the brain with the highest level of aerobic
glycolysis also express increased levels of genes relating to
synapse formation and growth, suggesting aerobic glycolysis
could be used in brain development to support the biosynthesis
required for growth, similarly to cancer cells (39). Others have also
suggested that the varying levels of aerobic glycolysis within the
human brain could be linked to the ratio of neurons to non-
neuronal cells (130). Aerobic glycolysis provides astrocytes with
the high energy requirements of the membrane bound Na+/K+-
ATPase pump, at the cell surface, to take up glutamate from the
synapse (98). According to the astrocyte–neuron lactate shuttle
theory, the glucose metabolized to lactate by astrocytes is secreted
and metabolized by neurons, which have no direct access to
glucose (44). LDHA clearly has an active role within the brain and
lactate has also recently been implicated as a neural intracellular
messenger (5), but further research is required to determine its
precise role.
Interestingly several mouse model studies have suggested that
loss of aerobic glycolysis in the brain is linked to Alzheimer’s
disease. APP/PS1 (APPswe, PSEN1dE9) double transgenic mice
are used as a model for Alzheimer’s disease and studies showed
that 12-month-old APP/PS1 mice had decreased PDK1 (pyruvate
dehydrogenase kinase isozyme 1), a promoter of aerobic
glycolysis, and LDHA expression in their frontal cortex compared
with age-matched controls (90). Furthermore, knockdown of
LDHA or PDK1 in B12, a rat CNS cell line, increased their
sensitivity to Aβ and other neurotoxins (90). Aβ deposition pro-
motes dysfunction of mitochondria, ROS (reactive oxygen
species) generation, and eventually leads to nerve cell death. By
elevating PDK1 and LDHA expression and promoting aerobic
glycolysis, the brain is protected (90). Furthermore, a
neuroimaging study in humans found that the regions of the brain
most susceptible to amyloid toxicity also exhibited high levels of
aerobic glycolysis (133); this has been suggested to be a preven-
tative protective measure against Aβ deposition and loss of this
protective mechanism may lead to Alzheimer’s disease (90).
However, a study in prematurely and normally aging mice found
failure of oxidative phosphorylation, thought to be caused mainly
by mitochondrial DNA point mutations, and elevated brain lactate
concentrations caused by increased LDHA transcription correlated
with an aging phenotype (109).
Changes in the cerebral spinal fluid (CSF) LDH isoenzyme
(Figure 2) concentrations can be used as an indicator of neurologi-
cal pathologies. For example, normal CSF contains very low con-
centrations of LDH-1 and LDH-2 LDH isoenzymes, whereas
LDH4 is elevated in tuberculous meningitis; LDH3 in pyogenic
meningitis and Guillain–Barré syndrome; LDH2 in viral encepha-
litis and LDH1 in hydrocephalus (52, 92). Elevated CSF concen-
trations of LDH are also seen in patients with ischemic stroke and
head injuries (96, 127). Furthermore, a study of leptomeningeal
metastases from solid and hematological tumors found that CSF
LDH concentrations could be used to help diagnosis and monitor
the patient’s response to treatment (127). There are several hypoth-
eses for the cause of increased CSF LDH concentrations, including
disruption of the blood brain barrier (BBB) which allows an
increased outflow of serum, release of LDH from cytolytic cells,
elevated synthesis of LDH in response to vascular damage or
reduced removal of LDH (96). Further research is required to
determine the mechanisms of CSF LDH upregulation and its reli-
ability as a prognostic marker for brain tumors.
LDHA AND TUMOR MALIGNANCY
Abnormal LDHA upregulation and LDHB downregulation is a
common characteristic of tumors, which promotes a metabolic
switch to aerobic glycolysis, generating lactate as a by-product.
Elevated lactate concentrations have been shown to predict tumor
malignancy, recurrence, survival and metastasis in cancer patients
(9, 135, 136). Serum LDH concentrations have also been shown to
be a good prognostic marker of many types of cancer (50, 78, 91,
139). LDHA overexpression is also associated with many other
poor prognostic factors, including tumor hypoxia (111),
angiogenesis (59), proliferation and glucose uptake (41), as well
as resistance to chemotherapy (66) and radiotherapy (67).
Furthermore, in non-small-cell lung cancer, which commonly
metastasizes to the brain, LDHA expression and NF-κβ are syn-
ergistically associated with death and recurrence (88). Several
studies have also demonstrated that LDHA has a role in tumor
formation, maintenance and progression (27, 72, 75); however,
there has not been adequate research into the use of LDHA as a
prognostic marker for brain tumors.
THE ROLE OF LDHA IN TUMOR
GROWTH AND SURVIVAL
Several studies, including in vivo research, have attenuated LDHA
expression initiated by various mechanisms and reports predomi-
nantly indicate that LDHA suppression inhibits tumor cell prolif-
eration and survival (70, 72, 140, 145). However, Langhammer
et al found that the growth of clones with LDHA silenced was not
impeded in vitro, but the same LDHA-silenced clones had an
impaired growth rate in vivo, compared with the control cell lines
(70). Additionally, cell lines that rely more on glutaminolysis and
fatty acid synthesis are not affected by LDHA inhibition, whereas
cell lines that rely on the pentose phosphate pathway and
glycolysis are affected (8). Therefore, the importance of LDHA in
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cell growth and survival is likely to be dependent on tumor meta-
bolic phenotype, reliance on LDHA and microenvironmental
influences.
Predominantly, studies have found that LDHA indirectly pro-
motes tumor survival through protection from ROS, as the inhibi-
tion of LDHA forces cells to use oxidative phosphorylation in
order to generate ATP and mitochondrial ROS production is
usually elevated as a result (27, 49, 72). Multiple in vitro and in
vivo xenograft mouse model studies have found that LDHA knock-
down cells treated with N-acetyl-L-cysteine (NAC), an antioxidant
that breaks disulfide bonds, prevented or partially prevented the
induced generation of ROS and apoptosis (113, 137, 140). Fur-
thermore, Sheng et al showed that the knockdown of LDHA and
generation of ROS, which regulates the intracellular calcium con-
centration (103), caused a loss of mitochondrial membrane poten-
tial, release of cytochrome C, activation of caspase 9 and caspase
3, and finally apoptosis (113). In vivo xenografts of breast cancer
cell lines also found that cell lines with LDHA knocked down had
elevated Bax, cleaved PARP, cleaved caspase-9, cytosolic
cytochrome C and superoxide anion expression but decreased
Bcl-2 expression and mitochondrial membrane potential (137).
One group has specifically looked at the effect of LDHA inhibition
in p53+/+ and p53−/− tumors (134). They found that LDHA inhi-
bition in both p53+/+ and p53−/− caused increased ROS and
decreased ATP which lead to apoptosis, although p53+/+ cell lines
were more sensitive to LDHA silencing, but no effect was seen on
the viability of non-neoplastic cell linesARPE19 (retinal epithelia)
and WI38 (diploid lung fibroblasts) (2). The increased sensitivity
to LDHA inhibition in p53+/+ colorectal epithelial cancer cells
was caused by a p53-dependent increase in cellular NADH : NAD+
ratio, which resulted in downregulation of the activity of the p53
NAD+-dependent deactylator SIRT1 and therefore upregulated
acetylated, active tumor suppressor p53 (2). Furthermore,
LDHA suppression increased sensitivity of p53+/+ cancer cells to
EO9, a redox-dependent prodrug reduced by NADPH-quinone
oxidoreductase 1 (NQO1) (2).
LDHA may also inhibit apoptosis more directly. Indeed, an
immunohistochemical study of melanoma by Zhuang et al
revealed that not only did LDHA expression increase as the
disease progressed but it was strongly associated with the expres-
sion of the anti-apoptotic proteins Mcl-1 and Bcl-XL (153). Fur-
thermore, knockdown of LDHA has been shown to increase PARP
expression, decrease XIAP, Bcl-2 and Bcl-XL expression, and
attenuate the tumorigenicity of the pancreatic cell line BXPC-3,
reducing the tumor size and weight in vivo xenograft models (108).
Interestingly, recent studies have demonstrated that LDHA is
inhibited in the isocitrate dehydrogenase (IDH) subgroup of
glioma, which has characteristically slow progression, greater sur-
vival rates and better prognosis than the other glioblastoma
multiforme (GBM) subgroups (14). It has previously been shown
that 2-hydroxyglutarate (2-HG), produced by IDH mutant tumors,
promotes HIF1α degradation (58). Further in vitro and in vivo
xenograft studies by Chesnelong et al established that LDHA, a
HIF1α responsive gene, was underexpressed in different grades of
IDH mutated gliomas (14). Even brain tumor stem cell (BTSC)
lines that once had IDH mutations but lost their mutant IDH allele
and no longer produced 2-HG had silenced LDHA. These results
led to the discovery that the LDHA promoter was heavily
methylated (14). Furthermore, addition of mutant IDH to human
astrocyte cell lines was also associated with methylation of LDHA
promoter. To corroborate their findings, they analyzed data from
The Cancer Genome Atlas and REMBRANDT public databases;
they found that low expression of LDHA and high methylation of
the LDHA promoter was found in IDHmt glioblastoma (GBM)
patients and glioma patients whose tumors overexpressed LDHA
had a median survival of 16 months, whereas patients whose tumor
underexpressed LDHA had a median survival of >50 months (14).
As LDHA has previously been shown to be important in tumor
growth and progression in many other tumors, the silencing of
LDHA in gliomas with IDH mutations may be responsible in part
for the characteristically slow progression of gliomas with IDH
mutations. These findings should prompt further studies to estab-
lish if LDHA correlates with tumor growth in other types of brain
tumor.
There are several other possible mechanisms in which LDHA
may promote tumor growth. LDHA may be involved in promoting
the cancer stem cell phenotype; Zhang et al showed that LDHA
significantly correlates with Oct-4, a gene involved with embry-
onic stem cell self-renewal (145). They conducted in vitro and in
vivo studies using lentivirus-mediated siRNA against LDHA and
found that it reduced Oct-4 expression and tumorigenicity (145).
LDHA overexpression may also promote tumor growth by pre-
venting necrosis in hypoxic environments; Lewis et al noted that
tumors created from cell lines overexpressing c-Myc or c-Myc
target genes LDHA and Rcl were not significantly necrotic com-
pared with tumors from cell lines overexpressing c-Myc target
genes Rcl and VEGF (75). These observations show promise
and should be investigated in both primary and secondary brain
malignancies.
THE ROLE OF LDHA IN TUMOR
MIGRATION AND METASTASIS
Secondary brain metastases are the most common type of adult
brain tumor and the incidence is rising. Many cancers can
metastasize to the brain but the most common are melanoma,
breast, lung, kidney and colon cancer. LDHA expression corre-
lates with metastasis and poor patient prognosis in many tumors
(9, 41, 48, 50, 64, 153). The most frequently reported mechanism
by which LDHA modulates cell migration and invasion is through
the generation of lactate, as lactate alone has been shown to cor-
relate with the invasive ability of many tumors (140). Lactate
causes acidification of the microenvironment which promotes
tumor cell invasion by inducing apoptosis of normal cells
and pH-dependent activation of metalloproteinases (MMPs) and
cathepsins which degrade the extracellular matrix and
basement membranes (6, 53, 107, 123). Goetze and others
have used Transwell® Boyden chamber assays to show that addi-
tion of exogenous lactate increased migration tumors in a
concentration-dependent manner (37). Sheng and others also
showed that knockdown of LDHA reduced the expression of
MMP-2 and metastatic potential, using cell lines and xenograft
mouse models (113). Furthermore, they found that the knockdown
of LDHA caused an increase in the tumor suppressor E-cadherin
and therefore cell–cell adhesion, and a loss of focal adhesion
kinase (FAK) and VEGF, both of which are also associated with
tumor metastasis, considerably implicating LDHA as a regulator
of invasion (113). There have been a few studies of LDHA and
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lactate in high-grade glioma migration. Seliger et al found that the
knockdown of LDHA resulted in a decrease in lactate concentra-
tion, which caused a reduction of THBS-1 and TGF-β2 expression
and reduced migration by approximately 40% compared with the
control siRNA (110). Furthermore, addition of lactate or synthetic
THBS-1 rescued TGF-β2 expression and glioma migration (110).
In another study, it was found that MMP-2, a promoter of migra-
tion and invasion which is overexpressed in high-grade glioma, is
also upregulated by LDHA through lactate induction of TGF-β2
(6).
Arseneault et al reported another mechanism in which LDHA
may regulate cell migration. They found that elevated
mitochondrial ROS production, caused by LDHA-targeted knock-
down using shRNA, is associated with compromised actin dynam-
ics, oxidation of tropomyosin isoform Tm5 and decreased cell
motility in the melanoma-derived cell line MDA-MB-435 (3). In
wound healing and transwell migration assays, migration of clonal
MDA-MB-435 cell lines with knocked down LDHAwas consider-
ably decreased. Furthermore, addition of antioxidant NAC
increased migration of a LDHA knockdown cell line in a
concentration-dependent manner. Together, their studies suggest
that LDHA may influence cell migration through mitochondrial
ROS production, Tms and redox regulation (3). Collectively, these
studies suggest that LDHA-targeted therapy could reduce tumor
invasion andmigration,which severely decreases a patient’s chance
of survival, especially in the context of primary brain tumor.
THE ROLE OF LDHA IN ANGIOGENESIS
Angiogenesis is a hallmark of many tumors, including GBMs, and
is stimulated by angiogenic factors including VEGF and IL-8.
Koukourakis et al published a number of immunohistochemical
studies showing an association between LDHA expression and
activation of the VEGF pathway (36, 59, 62, 65, 66). They found
that a high level of LDHA in the cytoplasm correlated significantly
with cytoplasmic VEGF expression (62), while LDHA expression
was significantly associated with phosphorylated VEGFR2 in both
tumor-associated vasculature and tumor cells (36). Another group
used a tissue microarray and found that high LDHA and VEGF
expression in tumor and stroma was a prognostic factor for gastric
tumors (54). However, these associations could be partly due to
VEGF and other angiogenic factors also being a target of the
LDHA transcription factors, HIF1 and c-Myc. Furthermore, other
immunohistochemical studies by Koukourakis et al found a sig-
nificant correlation between LDHA, HIF1α and an aggressive
phenotype. However, there was no association found between
LDHA expression and VEGF or vascular density (64, 65).
Interestingly, an acute acidic extracellular pH, which can be
caused by elevated lactate production, has been shown to promote
upregulation of IL-8 and VEGF independently of hypoxia (7, 35,
45, 115, 142). Studies in wound healing mouse models have shown
that sustained, local and systemic lactate release from subcutane-
ous implants of poly-D,L-lactide-co-glycolide (PGLA) promotes
angiogenesis and accelerates wound closure (101). A study where
Hunt–Schilling wound cylinders were implanted into rats estab-
lished that increased extracellular lactate concentrations in wounds
caused an elevation of interleukin-1β, VEGF (twofold) and
TGF-β1 (two- to threefold), a 50% increase in collagen deposition
and a 90% reduction of insulin-like growth factor-1 (125).Another
study in HUVEC (human umbilical vein endothelial cells) cells
cultured with 10 mM lactate found that VEGF and VEGFR2 were
significantly upregulated (69). Furthermore, the VEGF expressed
in the presence of lactate was of a more active form, as VEGF
PAR-modification decreased from 76% in the control to 21% in
lactate-treated cells (69). Another group developed a novel in vivo
microscopy technique in order to simultaneously measure tissue
oxygen partial pressure (pO2), pH and VEGF promoter activity in
human glioma cells (35). They found that VEGF expression was
independently regulated by pH and tissue pO2. Furthermore,
hypoxia and acidic pH did not have a synergistic effect on VEGF
transcription (35).
LDH concentrations may also be useful to predict whether
patients will benefit fromVEGF targeted therapies (13).A study of
tissues from 179 colorectal cancer patients showed that patients
treated with an anti-angiogenic drug (Vatalanib) and cytotoxic
chemotherapy [oxaliplatin/5-fluorouracil (FOLFOX) (Bayer
Schering Pharma AG, Berlin; Novartis, East Hanover, NJ, USA)]
combination had an improved response rate and progression-free
survival if their tumor expressed elevated LDHA compared to
patients with tumors expressing low levels of LDHA (66). Fur-
thermore, a clinical trial of the anti-angiogenesis drugs
bevacizumab and cediranib on advanced colorectal cancer patients
established that patients with high concentrations of serum LDHA
(treated with cediranib) had better overall survival (OS), whereas
patients with low concentrations of serum LDHA (treated with
bevacizumab) had a better OS, although these results were not
significant (4). Several studies suggest that LDHA could be
involved in the promotion of angiogenesis, but further research is
required to determine the exact mechanism that could then be
targeted for therapies in the future.
THE ROLE OF LDHA IN TUMOR
EVASION OF THE IMMUNE RESPONSE
It has been reported that a poor lymphocyte response occurring at
the invading tumor edge is associated with carcinomas expressing
high levels of LDHA (36). In addition, low lymphocyte response
was associated with 17 out 20 non-Hodgkin’s lymphoma patients
who had a medium or high LDHA expression (78). Again, it is
thought that lactate generation, promoted by LDHA, is the pre-
dominant cause of LDHA-mediated inflammation (117) and
evasion of the immune response (45) by inhibiting monocyte
migration (37) and differentiation to dendritic cells (38) and by
inhibiting cytotoxic T cell and dendritic cell cytokine release (30).
Like tumor cells, activated T cells are highly proliferative and use
glycolysis as their primary energy source. However, in the high
lactate environment surrounding the tumor, activated T cells
cannot secrete their own lactate, which depends on the intra- to
extracellular concentration gradient of lactate (30, 152).
Conversely, regulatory T cells do not use glycolysis as their
primary energy source and are not affected by the high lactate
concentrations (84).
In brain tumors, a study in GBMs revealed that LDHA, secreted
by the tumor, induced the transcription and expression of natural
killer group 2 member D (NKG2D) ligands, ULBP-1 (UL16
binding protein 1) and MICB [major histocompatibility complex
(MHC) class I chain-related B)], on circulating monocytes and
tumor infiltrating myeloid cells (18). Chronic exposure to NKG2D
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ligands expressed by monocytes downregulates the expression of
NKG2D receptors on natural killer cells, preventing their ability to
lyse NKG2D ligand-expressing tumor cells (93). Previous studies
in glioma have shown that TGF-β can also decrease NKG2D
expression on NK cells in vitro (17). As discussed previously,
lactate production by LDHA activates TGF-β in glioma (6); there-
fore, it is possible that LDHA also activates TGF-β to promote
evasion of the immune response. This phenomenon should be
investigated further.
LDHA AND THE TUMOR
MICROENVIRONMENT
Because of excessive tumor growth, the tumor microenvironment
is often hypoxic and acidic which can effect protein expression.
Oxygen levels often vary within a tumor, for example, GBMs have
oxygenated areas around the tumor vasculature, as well as areas of
oxygen-deprived cells and necrosis. GBMs are well known to
display intratumor heterogeneity which is caused, in part, by the
microenvironment and also makes them more adaptable to small
fluctuations within the microenvironment. As mentioned previ-
ously, hypoxia promotes transcription of LDHA by HIF-1 and
upregulation of LDHA causes lactate production, decreasing pH
levels. Sørensen et al conducted experiments to closely examine
LDHA mRNA expression in response to various oxygen and
extracellular pH (pHe) conditions. They found that, in a human
cervix squamous cell carcinoma cell line, after 24 h, LDHA
mRNA levels increased slightly as oxygen decreased from 21% to
0.01% at pHe 7.5, 7.0 and 6.7. Furthermore, at pHe 6.5 and 6.3,
and 1% oxygen, LDHA mRNA levels were six- to sevenfold
higher than at 21% oxygen (118, 119). When they repeated the
experiment in a pharyngeal squamous cell carcinoma cell line,
they found that LDHA mRNA expression also gradually increased
as oxygen concentrations decreased from 21% to 0.01%; however,
changes in pHe had little effect on LDHA mRNA expression
(119). These results indicate that LDHA expression in response to
the tumor microenvironment is regulated differently in different
tumors, which could be linked to the aggressiveness of the tumor
or metabolic phenotype.
LDHA can influence the tumor microenvironment through gen-
eration of lactate which lowers extracellular pH. Tumor pH can
also be variable within a tumor; using pH-sensitive electrodes,
primary brain tumors have been found to have a mean pH of 6.8
and as low as 5.9 compared with normal brain tissue which has a
pH of 7.1 (132). It has also been shown that an acidic pH induces
glioma stem cell markers and promotes angiogenesis and malig-
nancy; furthermore, in vitro elevation of pH reversed these effects
(46). It is conceivable therefore that LDHA is a major manipulator
of the tumor microenvironment, via lactate production and
decreasing the environmental pH, which promotes a cancer stem
cell phenotype, angiogenesis, migration and immune evasion.
LDHA AS A THERAPEUTIC TARGET
As discussed previously, LDHA is associated with tumor initia-
tion, maintenance, progression and poor prognosis in many
tumors. High serum LDH concentrations are also associated with
radio-resistance in both primary and metastatic brain tumors.
Moreover, multiple studies on various cell lines have shown that
attenuation of LDHA increases apoptosis (27, 72) (Figure 5) and
reduces migration and invasion ability (113, 140) demonstrating
its use as a potential therapeutic target. Mouse model studies have
found that LDHA deletion is embryonic-lethal; however, when
LDHA is switched off in the Cretm–LDHAfl/fl mouse model treated
with tamoxifen, mice develop severe, nonlethal hemolytic anemia
(141). Furthermore, human genetic defects in the LDHA gene are
also nonlethal but do cause glycogen storage disease type 11
(GSD11). Together, these studies suggest that LDHA inhibition
could be a well-tolerated therapy that will impede tumor growth
and metastasis.
To demonstrate the possible benefits of targeting LDHA as a
therapeutic target, as well as using LDHA-targeted siRNA and
shRNA, many studies have also used oxamate, an analog of
pyruvate that prevents LDH converting pyruvate to lactate and has
been shown to work synergistically with other current therapies.
Zhou et al showed that human breast cancer cells, which had
become resistant to the chemotherapeutic agent Taxol, had
increased levels of LDHA expression when compared to their
parental cells (152). Furthermore, they found that downregulation
of LDHA by using both LDHA-targeted siRNA and oxamate
increased the sensitivity of the Taxol-resistant cells to Taxol and
promoted apoptosis (152).
Miskimins et al conducted studies with oxamate and
phenformin on six different cancer cell lines. Phenformin inhibits
complex I in the mitochondria electron transport chain, causing
excess ROS production and is also associated with high incidence
Figure 5. Schematic showing the reported
mechanism in which lactate dehydrogenase A
(LDHA) inhibitors cause apoptosis in cancer
cells. Reported inhibitors of LDHA (listed in
Table 3) obstruct aerobic glycolysis and the
processes listed in Figure 3. Cancer cells are
then forced to use oxidative phosphorylation
and pyruvate enters the mitochondria. This
leads to reactive oxygen species (ROS)
generation and apoptosis.
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of lactic acidosis; however, oxamate reduced the lactic acidosis
side effect, and furthermore, it had a synergistic anti-cancer effect
when treated in combination with phenformin, reducing tumor
size, glucose uptake, ATP generation and increasing tumor
apoptosis in vivo (86). Oxamate also increased the sensitivity of
nasopharyngeal cancer cell lines to ionizing radiation, synergisti-
cally enhancing apoptosis and suppressed the growth of tumor
xenografts (144).
One of the problems with oxamate is that it has limited cell
penetration; therefore, relatively high doses are required to have
any significant effect. However, Galloflavin, a synthesized LDHA
and LDHB inhibitor, has high levels of cell penetration.
Galloflavin inhibited the growth of well-differentiated (MCF-7),
chemotherapy-resistant (MCF-Tam) and aggressive triple negative
(MDA-MB-231) breast cancer cell lines, despite their metabolic
differences, with their mean IC50 around 125 μm (28). However,
this is still a higher concentration than commonly used in
chemotherapeutics. Preliminary toxicity data are, however, prom-
ising, as 400 mg/kg body weight injected i.p. into mice was not
lethal (81). Furthermore, the highest tested dose of Galloflavin
(250 μm) caused <30% reduction ofATP and lactate production of
normal human lymphocytes and lymphoblasts but had a mild
effect on their growth and survival (28).
Gossypol, a derivative of cotton seed oil, inhibits LDHA and
LDHC and is highly soluble at physiological pH (73). Further-
more, it has been shown to have cytotoxic effects against a range
of tumors, including glioma cell lines (16). Coyle et al found
that gossypol treatment of mouse xenograft models decreased the
mean weight of tumors by more than 50%, and furthermore,
the most sensitive glioma cell lines had higher LDHA expression
levels (16). Moreover, gossypol has been shown to be well
tolerated in clinical trials and has also shown promise in recurrent
malignant glioma trials (12, 15, 31, 120). Two more clinical
trials with gossypol and GBM have been completed
(NCT00540722 and NCT00390403) but the results are currently
unavailable. FX11 [3-dihydroxy-6-methyl-7-(phenylmethyl)-4-
propylnaphthalene-1-carboxylic acid] is a promising new
gossypol-derived specific LDHA small molecule inhibitor that has
recently become commercially available. Studies on human lym-
phoma and pancreatic cancer xenografts have shown that FX11
inhibited tumor progression and induced significant oxidative
stress and necrosis (72).
Recently, over 900 plant extracts commonly used in medicine
have been screened and their ability to inhibit LDHA was evalu-
ated. Forty-six herbs, including cinnamon, pink rose buds/petals,
rhodiola root, witch hazel root and wintergreen, significantly
inhibited LDHA, with IC50s <0.07 mg/mL. However, Chinese
gallnut (Melaphis chinensis gallnut), bladderwrack (Fucus
vesiculosus), kelp (Laminaria japonica) and babul (Acacia
arabica) had the lowest IC50s of less than 0.001 mg/mL (23).
Further investigations are required to identify the active com-
pounds within these plant extracts which could be used in future
therapies. High-throughput screening also identified quinoline
3-sulfonamides as NADH-competitive LDHA inhibitors. Lead
compounds had a 10- to 80-fold selectivity for LDHA over LDHB
and IC50s were 2–10 nm, but regrettably the use of quinolone
3-sulfonamides is unacceptable in vivo because of their
pharmacokinetic properties; having a low in vivo clearance and
being incompatible with oral bioavailability (8).
Other groups have designed and synthesized specific LDHA
inhibitor compounds. For example, Granchi et al developed
N-hydroxyindole-based (NHI) inhibitors of LDHA, which they
showed to inhibit pancreatic ductal adenocarcinoma growth, par-
ticularly under hypoxic conditions (40) and work synergistically
with gemcitabine (first-line standard treatment) (80). They also
found that the novel NHI LDHA inhibitors significantly reduced
MMP-2 and MMP-9 expression under hypoxia which they hypoth-
esize to be the cause of the attenuated cell migration and invasion
observed (80). Moorhouse etal designed novel bifunctional
ligands that inhibit LDHA, by synthesizing “NADH-like” and
“substrate-like” azido and alkyne functionalized fragments and
linking them together to form 31 novel compounds. The compound
that showed the most promise for further development had a rela-
tively low IC50 of 14.8 mM, and a ninefold better activity against
LDHA than sodium oxamate (87). Another group found that
Mn(II) complexes, good functional mimics of catalase, inhibit
LDHA and also decreased HIF1α expression in the HepG-2 cell
line (143). Together, these studies show that designing small drug-
like molecules to target LDHA is achievable and able to hinder
tumor growth and maintenance but many still require further
development to improve their specificity and potency.
Targeting LDHA and tumor metabolism downstream of
pyruvate generation is an attractive option for cancer therapies as
the effect on the metabolism of normal cells should be minimal.
Although studies have clearly demonstrated the therapeutic poten-
tial of inhibiting LDHA in cancer patients, most current inhibitors
(Table 3) affect more than one of the LDH genes, have low potency
and require unacceptably high doses (which may also be affecting
other unknown nonspecific targets) to achieve the desired effect
and therefore are not suitable for clinical use. As described earlier,
many groups are in the early stages of identifying and designing
compounds which could eventually be used as LDHA inhibitors in
clinical trials; however, it is of note that most novel LDHA inhibi-
tors appear to be focused on targeting the LDHA enzyme activity
rather than the protein expression itself. Nonetheless, studies
showing synergistic effects of LDHA inhibitors in combination
with other therapeutics such as radiation, phenformin, taxol and
gemcitabine are promising. Although a few studies of LDHA in
brain tumors have shown promise, the extent of these studies is
severely lacking. Brain tumors are often more difficult to treat than
other cancers as therapeutic drugs often have limited propensity to
cross the protective BBB. However, to our knowledge, no groups
have tested whether any potential LDHA inhibitors are able to
cross the BBB.
Table 3. List of reported lactate dehydrogenase A (LDHA) inhibitors.
LDHA inhibitor Reference
Oxamate (86, 144, 152)
FX11 (72)
Galloflavin (28, 81)
Gossypol (12, 15, 16, 31, 120)
Quinoline 3-sulfonamides (8)
N-hydroxyindole-based (NHI) inhibitors (40)
Bifunctional ligands (87)
Mn(II) complexes (143)
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CONCLUSIONS
LDHA is clearly more than just a metabolic gene that is
overexpressed in cancer and the true extent of its function and the
exact mechanism in which it operates in non-neoplastic and neo-
plastic cells is only just beginning to come to light. Extensive
studies have shown that LDHA is involved directly and indirectly in
many aspects of tumor growth, migration, invasion and mainte-
nance in a wide range of tumors (Figure 3). Despite the promising
findings of a few studies presented here, the significance of LDHA
in normal brain function and brain tumor initiation and progression
is an area of research that is not receiving enough attention. More
research conducted on the less studied roles of LDHA should also
be encouraged as findingswill, no doubt, benefit the ongoing search
for suitable LDHA inhibitors which could be used in future clinical
trials. It is also imperative to keep the issue of crossing the BBB in
mind when designing LDHA inhibitors.
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